-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Altamira Therapeutics (NASDAQ:CYTO) Shares Down 2.9%
Altamira Therapeutics (NASDAQ:CYTO) Shares Down 2.9%
Altamira Therapeutics Ltd. (NASDAQ:CYTO – Get Rating) fell 2.9% during trading on Friday . The company traded as low as $0.35 and last traded at $0.38. 125,689 shares traded hands during trading, a decline of 87% from the average session volume of 980,736 shares. The stock had previously closed at $0.39.
Altamira Therapeutics Price Performance
The firm's fifty day moving average price is $0.43 and its 200 day moving average price is $0.68.
Get Altamira Therapeutics alerts:Hedge Funds Weigh In On Altamira Therapeutics
A hedge fund recently raised its stake in Altamira Therapeutics stock. BlackRock Inc. grew its stake in Altamira Therapeutics Ltd. (NASDAQ:CYTO – Get Rating) by 84.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 61,603 shares of the company's stock after acquiring an additional 28,151 shares during the quarter. BlackRock Inc. owned about 0.41% of Altamira Therapeutics worth $67,000 at the end of the most recent quarter. Institutional investors and hedge funds own 9.75% of the company's stock.
Altamira Therapeutics Company Profile
(Get Rating)Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss.
Recommended Stories
- Get a free copy of the StockNews.com research report on Altamira Therapeutics (CYTO)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Altamira Therapeutics Ltd. (NASDAQ:CYTO – Get Rating) fell 2.9% during trading on Friday . The company traded as low as $0.35 and last traded at $0.38. 125,689 shares traded hands during trading, a decline of 87% from the average session volume of 980,736 shares. The stock had previously closed at $0.39.
阿爾塔米拉治療有限公司(納斯達克代碼：Cyto-Get評級)在週五的交易中下跌2.9%。該公司股價低至0.35美元，最新報0.38美元。當日成交量為125,689股，較當日平均成交量980,736股下降87%。該股此前收盤價為0.39美元。
Altamira Therapeutics Price Performance
阿爾塔米拉治療藥物性價比
The firm's fifty day moving average price is $0.43 and its 200 day moving average price is $0.68.
該公司的50日移動均線價格為0.43美元，200日移動均線價格為0.68美元。
Hedge Funds Weigh In On Altamira Therapeutics
對衝基金入股阿爾塔米拉治療公司
A hedge fund recently raised its stake in Altamira Therapeutics stock. BlackRock Inc. grew its stake in Altamira Therapeutics Ltd. (NASDAQ:CYTO – Get Rating) by 84.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 61,603 shares of the company's stock after acquiring an additional 28,151 shares during the quarter. BlackRock Inc. owned about 0.41% of Altamira Therapeutics worth $67,000 at the end of the most recent quarter. Institutional investors and hedge funds own 9.75% of the company's stock.
一家對衝基金最近增持了阿爾塔米拉治療公司的股票。根據貝萊德公司提交給美國證券交易委員會的最新的13F文件，今年第一季度，該公司在阿爾塔米拉治療有限公司(納斯達克：Cyto-Get Rating)的持股增加了84.2%。該公司在本季度增持了28,151股後，持有61,603股該公司股票。截至最近一個季度末，貝萊德擁有阿爾塔米拉治療公司約0.41%的股份，價值67,000美元。機構投資者和對衝基金持有該公司9.75%的股票。
Altamira Therapeutics Company Profile
阿爾塔米拉治療公司簡介
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss.
阿爾塔米拉治療有限公司致力於開發解決各種未得到滿足的醫療需求的療法。它的商業產品包括Bentrio，一種用於個人防護空氣傳播病毒和過敏原的無藥物鼻噴霧劑。該公司還參與了用於肝外治療靶點的RNA療法的開發，包括處於寡核苷酸和信使核糖核酸輸送的臨牀前階段的寡聚和信號燈平臺；用於鼻腔治療眩暈的AM-125處於第二階段臨牀試驗；用於治療急性內耳耳鳴的Keyzilen處於第三階段臨牀試驗；以及用於治療急性內耳聽力損失的Sonsuvi處於臨牀開發第三階段。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Altamira Therapeutics (CYTO)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- 免費獲取StockNews.com關於阿爾塔米拉治療公司(Cyto)的研究報告
- 股市：紅海中的三座強國
- 第四季度值得考慮的3家銀行
- 有什麼辦法可以治癒Teladoc股票的問題嗎？
- 沒有人告訴這三隻股票這是下跌的一週
- MarketBeat：回顧一週9/12-9/16
Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《阿爾塔米拉治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對AlTamira治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧